FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 100 Summer Street, Suite 2300 Boston, Massachusetts 02110 (Address of Principal Executive Offices) (Zip Code) (617) 621-7722 (Registrant's telephone number, including area code) For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Class A Common Stock, $0.001 par value | IRWD | Nasdaq Global Select Market | Securities registered pursuant to Section 12(g) of the Act: None Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION ...

| --- | --- | --- | |-------------------------|-------|-------| | | | | | Ironwood 4Q and FY 2020 | | | Ironwood Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; the Company's strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linaclotide), ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2020 Earnings Conference Call February 17, 2021 8:30 AM ET Company Participants Meredith Kaya - VP, IR and Corporate Communications Mark Mallon - CEO Thomas McCourt - President Gina Consylman - SVP and CFO Michael Shetzline - CMO, SVP and Head of Drug Development Conference Call Participants Unidentified Analyst - Credit Suisse Eric Joseph - J.P. Morgan Boris Peaker - Cowen and Company Jacob Hughes - Wells Fargo Operator Ladies and gentlemen, thank you for sta ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2020 Results Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Meredith Kaya - Vice President, Investor Relations and Corporate Communications Mark Mallon - Chief Executive Officer Mark Plinio - Chief Commercial Officer Gina Consylman - Chief Financial Officer Mike Shetzline - Chief Medical Officer Conference Call Participants David Lebowitz - Morgan Stanley Eric Joseph - JP Morgan Tim Chiang - Northland Securities Operator Ladies and g ...

| --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------| | | | | | | | Ironwood 3Q 2020 Investor Update | | | | | | November 5, 2020 | | | | | | | | | | | | | | | | | | | | | | | Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision to become a leader in GI; our a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 100 Summer Street, Suite 2300 Boston, Massachusetts 02110 (Address of Principal Executive Offices) (Zip Code) (617) 621-7722 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Washington, D.C. 20549 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34620 IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR IRONWOOD PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 04-3404176 (I.R.S. Employer Identification Number) 100 Summer Street, Suite 2300 Boston, Massachusetts (Addre ...